Abstract:AimRecent studies indicate that pirfenidone (PFD) may have anti-fibrotic effects in many tissues, but the potential molecular mechanism remains unknown. The purpose of this study is to investigate the potential effects of PFD on epithelial-to-mesenchymal transition (EMT) and renal fibrosis in a unilateral ureteral obstruction (UUO) rat model and the involved molecular mechanism related to cultured human renal proximal tubular epithelial cells (HK-2). MethodsSixty rats were randomly divided into three groups: sham-operated, vehicle-treated UUO, and PFD-treated UUO. Kidney specimens were collected at day 7 or 14 after UUO. PFD treatment was also performed for human HK-2. The tubulointerstitial injury, interstitial collagen deposition, and expression of type I and III collagen, -SMA, S100A4, fibronection and E-cadherin were assessed. In addition, extracellular signal regulated kinase (ERK1/2), p38 MAPK (p38), and c-Jun N-terminal kinase/stress-activated protein kinase (JNK) were also detected. ResultsIn vitro, PFD significantly attenuated TGF-1-induced EMT and extracellular matrix (ECM) synthesis, as determined by reducing expression of -SMA, type I and III collagen, S100A4, fibronection, and increased expression of E-cadherin. PFD treatment attenuated TGF-1-induced up-regulation of phosphorylation of ERK1/2, p38 and JNK. In vivo, PFD reduced the degree of tubulointerstitial injury and renal fibrosis, which was associated with reduced expression of TGF-1, type III collagen, -SMA, S100A4, fibronection, and increased expression of E-cadherin. ConclusionThese results suggest that pirfenidone is able to attenuate EMT and fibrosis in vivo and in vitro through antagonizing the MAPK pathway, providing a potential treatment to alleviate renal tubulointerstitial fibrosis. Summary at a Glance This study demonstrated the efficacy of the pirfenidone to improve renal fibrosis in both an experimental rodent model, UUO and on epithelial-to-mesenchymal transition and fibrotic markers in cultured human proximal tubular cells. Pirfenidone is an anti-fibrotic drug used in the treatment of idiopathic pulmonary fibrosis. Hence pirfenidone could be further investigated as a potential treatment to alleviate renal tubulointerstitial fibrosis.

Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy

Fluorofenidone Attenuates Tubulointerstitial Fibrosis by Inhibiting TGF-β1-Induced Fibroblast Activation

[Effect of Fluorofenidone on Renal Interstitial Fibrosis in Rats with Unilateral Ureteral Obstruction].

The Protective Mechanism of Fluorofenidone in Renal Interstitial Inflammation and Fibrosis

Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction.

Fluorofenidone protects against renal fibrosis by inhibiting STAT3 tyrosine phosphorylation

Effect of Pirfenidone on renal interstitial fibrosis in rats

Fluorofenidone Attenuates Oxidative Stress and Renal Fibrosis in Obstructive Nephropathy Via Blocking NOX2 (gp91phox) Expression and Inhibiting ERK/MAPK Signaling Pathway

Fluorofenidone Inhibits Nicotinamide Adeninedinucleotide Phosphate Oxidase Via PI3K/Akt Pathway in the Pathogenesis of Renal Interstitial Fibrosis

Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage

Fluorofenidone Attenuates Renal Interstitial Fibrosis by Enhancing Autophagy and Retaining Mitochondrial Function

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

Fluorofenidone attenuates interleukin-1β production by interacting with NLRP3 inflammasome in unilateral ureteral obstruction.

FFNT25 Ameliorates Unilateral Ureteral Obstruction-Induced Renal Fibrosis.

Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway

Pirfenidone Suppresses MAPK Signalling Pathway to Reverse Epithelial-Mesenchymal Transition and Renal Fibrosis

Fluorofenidone Attenuates Collagen I and Transforming Growth Factor‐β1 Expression Through a Nicotinamide Adenine Dinucleotide Phosphate Oxidase‐dependent Way in NRK‐52E Cells

Fluorofenidone Inhibits TGF-beta1 Induced CTGF Via MAPK Pathways in Mouse Mesangial Cells.

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Paeoniflorin of Paeonia Lactiflora Prevents Renal Interstitial Fibrosis Induced by Unilateral Ureteral Obstruction in Mice